We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

INTC:NASDAQIntel Corporation Analysis

Data as of 2026-05-25 - not real-time

$119.84

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Intel (INTC) has staged a spectacular rally in 2026, with the stock up more than 220% YTD and trading near $120, well above its DCF‑derived fair value of roughly $22. Technical momentum is strong: the 20‑day SMA (~$109) sits comfortably below the current price, the 50‑day SMA (~$76) and 200‑day SMA (~$47) are all far beneath, and the trend direction is flagged as bullish. However, the RSI sits at 68, edging into overbought territory, and the MACD histogram is negative with a bearish signal line, hinting at possible short‑term weakness. Fundamentally, the picture is mixed: revenue growth is modest at 7.2%, but profit margin is negative (‑5.9%) and free cash flow remains deeply negative, while debt‑to‑equity is an elevated 36× and forward P/E is 77 versus an industry average of 39. Recent news of a preliminary Apple chip deal and talks with SK Hynix have reignited confidence in the foundry segment, yet the valuation gap and high beta (≈2.4) keep risk levels elevated. Overall, the stock is riding a wave of optimism that may be outpacing underlying earnings reality, suggesting caution despite the headline‑grabbing gains.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 7/10

Key Factors

  • Recent Apple chip partnership boosting market sentiment
  • Bullish SMA alignment but RSI approaching overbought
  • Bearish MACD signal indicating possible near‑term pullback

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Continued product launches (Core Ultra) and foundry expansion
  • Persistently negative free cash flow and high leverage
  • Valuation still far above DCF fair value and sector peers

Long Term

> 3 years
Cautious
Model confidence: 8/10

Key Factors

  • Negative profit margins and ROE indicating earnings weakness
  • DCF fair value suggests a downside of over 25% from current price
  • High beta and volatility expose the stock to market swings

Key Metrics & Analysis

Financial Health

Revenue Growth7.20%
Profit Margin-5.90%
P/E Ratio77.8
ROE-2.91%
ROA0.63%
Debt/Equity36.03
P/B Ratio5.4
Op. Cash Flow$10.0B
Free Cash Flow$-8301250048
Industry P/E39.5

Technical Analysis

TrendBullish
RSI68.2
Support$80.80
Resistance$132.75
MA 20$109.06
MA 50$76.45
MA 200$47.17
MACDBearish
VolumeDecreasing
Fear & Greed Index91.8

Valuation

Fair Value$22.14
Target Price$87.86
Upside/Downside-26.68%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta2.40
Volatility97.44%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.